Hypertension-Linked Mutation of \( \alpha \)-Adducin Increases CFTR Surface Expression and Activity in HEK and Cultured Rat Distal Convoluted Tubule Cells

Anna Mondini\(^1\), Francesca Sassone\(^1\), Davide Antonio Civello\(^1\), Maria Lisa Garavaglia\(^1\), Claudia Bazzini\(^1\), Simona Rodighiero\(^2\), Valeria Vezzoli\(^1\), Fabio Conti\(^3\), Lucia Torielli\(^3\), Giovanbattista Capasso\(^4\), Markus Paulmichl\(^5\), Giuliano Meyer\(^1\)*

1 Department of Life Sciences, Università degli Studi di Milano, Milano, Italy, 2 Fondazione Filarete, Milano, Italy, 3 Praxis Research Institute, Sigma Tau,settimo M.se, Italy, 4 Department of Internal Medicine, Second University of Napoli, Napoli, Italy, 5 Institut of Pharmacology and Toxicology, Paracelsus Medical University, Salzburg, Austria

Citation: Mondini A, Sassone F, Civello DA, Garavaglia ML, Bazzini C, et al. (2012) Hypertension-Linked Mutation of \( \alpha \)-Adducin Increases CFTR Surface Expression and Activity in HEK and Cultured Rat Distal Convoluted Tubule Cells. PLoS ONE 7(12): e52014. doi:10.1371/journal.pone.0052014

Abstract

The CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) activity and localization are influenced by the cytoskeleton, in particular by actin and its polymerization state. In this study we investigated whether the expression of the hypertensive mutations of \( \alpha \)-adducin (G460W-S586C in humans, F316Y in rats), an actin capping protein, led to a functional modification of CFTR activity and surface expression. The experiments were performed on HEK293 T cells cotransfected with CFTR and the human wild type (WT) or G460W mutated \( \alpha \)-adducin. In whole-cell patch-clamp experiments, both the CFTR chloride current and the slope of current activation after forskolin addition were significantly higher in HEK cells overexpressing the G460W adducin. A higher plasma membrane density of active CFTR channels was confirmed by cell-attached patch-clamp experiments, both in HEK cells and in cultured primary DCT cells, isolated from MHS (Milan Hypertensive Strain, a Wistar rat (Rattus norvegicus) hypertensive model carrying the F316Y adducin mutation), compared to MNS (Milan Normotensive Strain) rats. Western blot experiments demonstrated an increase of the plasma membrane CFTR protein expression, with a modification of the channel glycosylation state, in the presence of the mutated adducin. A higher retention of CFTR protein in the plasma membrane was confirmed both by FRAP (Fluorescence Recovery After Photobleaching) and photoactivation experiments. The present data indicate that in HEK cells and in isolated DCT cells the presence of the G460W-S586C hypertensive variant of adducin increases CFTR channel activity, possibly by altering its membrane turnover and inducing a retention of the channel in the plasmamembrane. Since CFTR is known to modulate the activity of many other transport systems, the increased surface expression of the channel could have consequences on the whole network of transport in kidney cells.

Introduction

Adducins (\( \alpha \), \( \beta \), and \( \gamma \)) are cytoskeletal F-actin end-capping proteins that play a role in restricting actin filament length [1], by binding directly to F-actin and bundling actin filaments [2]. Furthermore they promote the binding of spectrin to actin [3,4], thus regulating the assembly of the subcortical cytoskeletal membrane network [5]. In epithelial cells, adducin is associated with the spectrin-based membrane skeleton and spectrin-adducin-ankyrin complexes link membranes to the actin cytoskeleton [6]. In this cell type adducins are especially abundant at cell-cell contact sites [7] and are also present in the clathrin-coated vesicle (CCV) compartment, associated with clathrin [8].

Both in a cell free system and in a kidney cell line, \( \alpha \)-adducin mutations (F316Y and G460W-S586C in rats and humans respectively) interfere with actin assembly and polymerization, leading to a higher final level of filamentous actin [9]. These adducin mutations have also been found to be significantly related to Na\(^+\)/K\(^+\)-sensitive hypertension development by influencing cation and anion transport mechanisms in renal epithelia [10–13].

In renal epithelial cells, the transfection with mutated (F316Y) rat \( \alpha \)-adducin induces an increase in Na\(^+\)/K\(^+\)-pump activity [9]. This upregulation is in part depending on a decrease of pump endocytosis from the basolateral membrane [8], likely because of increased adaptor protein 2 (AP-2) phosphorylation [14]. Furthermore in vitro, mutated adducin variants have been shown to directly activate the Na\(^+\)/K\(^+\)-ATPase, by accelerating the rate of conformational change [13] and increasing Src-dependent Na\(^+\)/K\(^+\)-ATPase phosphorylation and activity [15].

Na\(^+\)/K\(^+\)-ATPase is not the only renal transport system affected by mutations of the adducin gene. In Thick Ascending Limb (TAL) and Distal Convoluted Tubule (DCT) cells of Milan...
Hypertensive rats (MHS), a model system of Na*-sensitive hypertension bearing the F316Y adducin mutation [16], an increase of the activity and/or expression of NKCC2 [17,18], NCC (Na+-Cl– cotransporter), and of ClC-K chloride channels has been observed [11], suggesting that adducin mutations can directly or indirectly impact on several Na* and Cl– transport systems, especially in the distal segments of the nephron.

CFTR is one of the chloride channels expressed in the kidney. Its expression and functional activity has been demonstrated in several nephron tracts such as DCT, cortical collecting duct (CCT) and inner medullary collecting duct [19]. Despite the broad distribution, the role of CFTR in the kidney remains uncertain as there is no major disruption of renal function in cystic fibrosis patients [20], apart from a reduced renal excretion of NaCl. Nevertheless, CFTR is also a regulatory protein influencing the activity and localization of other membrane proteins as well and other renal Cl– and Na* channels and transporters could be influenced by CFTR [19,21,22], as observed in several cell types [23]. In proximal tubular cells, CFTR is present in intracellular vesicles along both the exocytic and the endocytic pathways, where by ensuring the chloride conductance dissipating the potential difference originated by the V-ATPase active H+-transport, it participates to endosomal acidification and therefore to receptor-mediated protein uptake by PT (proximal tubule) cells [24,25].

CFTR channel activity and expression are regulated, besides other several intracellular factors like PKA, also by the cytoskeleton. Changes in actin filament organization modulate CFTR channel activity by a mechanism entailing a direct interaction between actin filaments and CFTR [26]. Furthermore, CFTR intracellular dynamics and plasmamembrane expression are affected by cytoskeletal proteins. Efficient internalization of CFTR requires actin polymerization and association with the actin-binding motor protein Myosin VI [27,28]. The surface localization of CFTR is stabilized also by other interacting proteins, such as the multidomain cytoskeletal protein filamin [29] and the PDZ-containing adaptor molecule NHERF1/EBP50, that connects CFTR to the microtubules network [30] and to the cortical actin cytoskeleton [31]. CFTR surface expression is also regulated through its trafficking and endocytic recycling. It associates with SNARE proteins (syntaxin 1A, SNAP23) and endocytic adaptors such as AP-2, undergoing clathrin-mediated endocytosis [23,32]. A balance between cytoskeletal tethering and capture by the endocytic machinery may be crucial to maintain a sufficient population of CFTR at the cell surface.

Since the hypertensive adducin variants influence the cytoskeleton and the AP-2 mediated endocytosis, we investigated whether CFTR could be influenced by these adducin mutations too. We performed electrophysiological, biochemical and fluorescence experiments to evaluate the influence of the hypertension-linked human G460W-S586C adducin variant (G460W adducin) on CFTR activity, expression and trafficking. These experiments demonstrated that this adducin mutation can actually modulate CFTR activity and surface expression in HEK 293 cells. To explore the physiological implications of adducin influence on CFTR channel activity, we performed additional experiments on Milan Hypertensive Rats (MHS) rats DCT primary cultured cells. Patch-clamp experiments demonstrated a higher channel activity in MHS rat cells compared to the corresponding normotensive strain (MNS), thus suggesting a possible role for adducin as a regulator of CFTR channel activity also in vivo.

Materials and Methods

cDNA Constructs
cDNA encoding human CFTR was subcloned from pcDNA3, kindly provided from M. Conese (Università degli Studi, Foggia), into the following expression vectors: pIRE2-EGFP (Clontech) for patch-clamp experiments, pEVFP-N and pEVFP-C (Clontech) for FRET and FRAP experiments, PAGFP for photoactivation experiments. cDNA encoding for human WT or G460W adducin was subcloned from pcDNA3.1, kindly provided by M.G. Tripodi (Prassi, Sigma Tau, Milan), into pECFP-C and pECFP-N (Clontech) for FRET, FRAP and photoactivation experiments. In the case of FLAG coinmunoprecipitation experiments, a FLAG tag (sequence: DYKDDDDK) was inserted by mutagenesis (performed with QuikChange Site-Directed Mutagenesis Kit, Stratagene) at the C-terminus of adducin in the pcDNA3.1 vector, before the STOP codon. HA-immunoprecipitation experiments were performed by using the pcDNA3.1-HA-adducin vector [8]. All cDNA constructs were confirmed by sequencing.

Cell Culture and Transfection

Primary culture of DCT cells. Hypertensive male MHS Wistar rats (2 months old; body weight, 350 g) and corresponding control MNS were used. To obtain primary culture of DCT cells, DCT tubules were microdissected from the whole kidney according to a previously described method [11]. The experiments are in accordance with the Italian guidelines for laboratory animals (Protocol N° 5/2008). All surgery was performed under Avertin [2, 2, 2-Tribromoethanol] anesthesia, and all efforts were made to minimize suffering.

HEK cells. HEK293 cells stably transfected with WT (NU12 cells) or G460W (HU33 cells) z-adducin were kindly provided by Prassi, Sigma Tau, Milan [8]. Human embryonic kidney (HEK) 293T cells, NU12 and HU33 were cultured in MEM, 1% FBS and transiently transfected for FRET, Western blot or patch-clamp experiments as previously reported [33]. The maintenance of the expression of adducin was routinely assessed by Western blot and immunocytochemistry, as shown in Figure S1.

Patch-clamp Experiments

Patch-clamp experiments were performed on NU12 (HEK cells stably transfected with the human wild-type adducin) and HU33 cells (expressing the G460W mutation) transiently transfected with a human CFTR expressing bicistronic vector (pIRE2-EGFP-CFTR), that allows to express both CFTR and EGFP (Enhanced Green Fluorescent Protein) as two separate proteins. The pIRE2-EGFP vector, expressing only EGFP, was used as control. Adducin and CFTR expression has been verified by Western blot. For whole-cell experiments the pipette solution contained (mM) 140 NaCl, 10 tetraethylammonium chloride, 0.5 EGTA, 2 MgCl2, 2 Mg–ATP, 5 glucose and 5 HEPES (pH 7.2, 320 mOsm) and the bath solution contained (mM) 145 NaCl, 4 CaCl2, 1 CaCl2, 1 MgCl2, 10 glucose and 10 HEPES (pH 7.4), 324 mOsm. All experiments were performed at room temperature (22–25°C). Pipettes were pulled from borosilicate glass and had resistances of 3–5 MΩ after fire polishing. Seal resistances were typically between 3 and 10 GΩ. After establishing the whole-cell configuration, CFTR was activated by adding 10 µmol/L forskolin. Currents were recorded using an EPC9 amplifier (HEKA, Germany) and low-pass filtered at 1 kHz. Mean currents were normalized as current densities (pA/pF). Cell capacitance was not statistically different in HU33 and NU12 cells (NU12: 17.7±1.3 pF, n = 14; HU33: 19.6±1.0 pF, n = 12). Forskolin activation time course analysis was performed after complete
CFTR Cl records were leakage corrected: basal currents with no active voltage each of 2-s duration; holding voltage was 0 mV. All were obtained by averaging currents generated by 10 ramps of was calculated as previously reported [27]. Ramp I-V relationships channel in a patch, the open probability of the single channel (Po) frequency) was 1.65 ms. As we usually observed more than one the analyses, as filter risetime (tr = 0.3321/fc with fc = filter corner transitions during the course of an experiment, as described [34]. For open channels were subtracted from those showing CFTR membrane proteins was performed with the Plasma Membrane Protein Extraction Kit (MBL International Corporation), following manufacturer instructions. The reliability of plasma membrane separation has been verified by confirming the enrichment in the plasmamembrane fraction of cadherin, a plasmamembrane marker, compared to calreticulin, an endoplasmic reticulum marker (see Text S1 and Figure S2). Protein concentration in the samples was quantified by the Bradford assay (BioRad). All protein extracts were heated at 37°C for 20 minutes in SDS-PAGE solubilising buffer (57.85 mmol/l Tris HCl, 10% Glycerol, 2% SDS, 0.004% Bromophenol blue, pH 6.8) containing 7.5% Dithiothreitol, and microfuged for 1 minute. 100 μg of total proteins or 20 μg of membrane proteins were loaded in each lane and separated by SDS-PAGE-electrophoresis on a 6.5% polyacrylamide gel at 100 V for 2 hour. Following electrophoresis, proteins were transferred overnight onto a PVDF (Polyvinylidene Fluoride) membrane. After blocking in blocking buffer 1 (PBS pH 7.4, 2% semi-skimmed milk powder, 0.05% Tween-20) for 2 hours at room temperature, the membrane was incubated with the anti-CFTR 24.1 (R&D Systems) diluted 1:1000 in the blocking buffer at 4°C overnight, followed, after several washing steps, by the secondary HRP-conjugated antibody (1:10000) at room temperature for 1 hour. Detection was performed with the Immobilon ECL system (Millipore). In all other cases, after transfer, the membrane was exposed to blocking buffer 2 (PBS pH 7.4, 5% semi-skimmed milk powder, 0.1% Tween-20) for 1 hour at room temperature. In case of reprobing of the blot, the membrane was first exposed to a stripping solution (0.05 M glycin and 1% SDS) for 40 minutes at room temperature. The membrane was then incubated with the anti-cadherin (pan Cadherin antibody, Abcam, ab6529), anti-calreticulin (Calreticulin antibody, Abcam, ab4), anti-FLAG (FLAG M2 antibody, Sigma, F3165), anti-HA (HA antibody, Covance, Princeton, NJ) or anti-CFTR (CFTR H-182 antibody, Santa Cruz, sc-10747) antibody diluted in the blocking buffer at 4°C overnight. After several washing steps, membrane was exposed to secondary HRP-conjugated antibody at room temperature for 1 hour and washed before proceeding with the ECL detection.

At the end, the PVDF membrane was always stained with the amido black staining procedure in order to assess the efficiency of protein transfer and check for equal loading.

The densitometric analyses of the bands has been performed by means of the ImageJ software (NIH, USA).

Immunofluorescence

Layers of DCT cells plated on glass coverslip were fixed with 3% parafomaldehyde and permeabilized with 0.1% Triton X-100. Non-specific binding was blocked with 5% BSA. Cells were then incubated at the presence of the mouse anti-CFTR (CFTR H-182 antibody, Santa Cruz, sc-10747) primary antibody at room temperature for 1 hour, followed by Cy2 anti-rabbit (1:400 dilution, at room temperature for 1 hour) secondary antibody incubation (Jackson Labs). Images were acquired by a confocal microscope Leica TCS SP2 AOBS (Leica Microsystems, Heidelberg, Germany) provided with 63× Oil immersion objective (1.4 NA).

FRAP

HEK293 T cells were transiently transfected (PEI method) with YFP-CFTR and GFP-adducin WT or GFP-adducin G460W. The experiments were performed on cells co-expressing both proteins, 48 h after-transfection, maintaining the cells at 37°C in PBS complemented with 4.5% glucose during the confocal observation. For imaging, YFP was excited with the 514 nm laser line and

solution change in the chamber (within 30 s). The current amplitude was measured at a constant potential of +40 mV every 15 s until a steady state was obtained. The forskolin activation time course was fitted, using GraphPad Prism v5 software, with a sigmoidal function:

\[ Y = \frac{Y_{\text{min}} + (Y_{\text{max}} - Y_{\text{min}})}{1 + e^{-\sigma(t-t_0)^{-x}}} \]

Where \(Y_{\text{min}}\) and \(Y_{\text{max}}\) are the minimum and the maximum \(Y\) values (pA/pF) respectively, \(\sigma\) is the rate constant for the rise of the sigmoidal function, and \(t_0\) is the time interval from the start to the inflection point of the sigmoidal function.

For cell-attached patch-clamp experiments the bath solution was an HBSS solution (Sigma, Italy), buffered at pH 7.4 with 10 mM Hapes, 304 mMosm. The micropipette solution (cell-attached and inside-out configurations) contained (mM): 115 N-Methyl Ghacamine Cl, 30 TEACl, 2 CaCl2, 1 MgCl2, 10 HEPES (pH 7.4), 309 mMosm. All experiments were performed at room temperature (22–25°C). The patch pipette resistance was 5–10 MΩ, and seal resistance was 5–10 GΩ. Currents were recorded using a EPC9 amplifier (HEKA, Germany), digitized at 5 kHz and low-pass filtered at 0.2 kHz. The bath was earthed with an Ag/AgCl electrode immersed in the bath solution. Potential differences were expressed as overall potential differences, considering the junction potential, the holding potential, and the cell membrane potential, measured to be about -30 mV (current clamp experiments). Data analysis was performed by Bruxton Tac program. For single-channel studies of CFTR, voltage was stepped from −135 to +65 mV (overall potential) in 20 mV increments of 20 s duration. Slope conductance was calculated by dividing unitary current by the overall potential differences. The number of channels in a membrane patch was determined from the maximum number of simultaneous channel openings observed during the course of an experiment, as described [34]. For open probability (Po) analyses, lists of open and closed times were created using a half-amplitude crossing criterion for event detection. Transitions <3.32 ms in duration were excluded from the analyses, as filter risetime (\(t_\text{r} = 0.3321/fc\) with \(fc = \text{filter corner frequency}\)) was 1.65 ms. As we usually observed more than one channel in a patch, the open probability of the single channel (Po) was calculated as previously reported [27]. Ramp I-V relationships were obtained by averaging currents generated by 10 ramps of voltage each of 2-s duration; holding voltage was 0 mV. All records were leakage corrected: basal currents with no active CFTR Cl⁻ channels were subtracted from those showing CFTR activity before averaging subtracted currents to generate the ensemble ramp I-V relationship of CFTR Cl⁻ currents [11].

Western Blot

CFTR expression was assessed using the monoclonal anti-CFTR 24.1 antibody (R&D System) on lysates obtained from HEK293 clones stably expressing HA-tagged ζ-adducin WT (clone NU12) or G460W (clone NU12) and transiently expressing CFTR. Transfection efficiency has been verified by immunofluorescence and by the luciferase reporter methods (see supplemental material) and, with both methods, it was not significantly different between HU33 and NU12 cells (Figure S2). HU33 and NU12 cells transiently expressing CFTR were lysed in Triton lysis buffer (TLB: 1% Triton, 25 mmol/l Tris pH 7.4, 150 mmol/l NaCl) and protease inhibitors, (Complete EDTA-free Protease Inhibitor Cocktail (Roche). The lysate was spun at 20000 g for 20 min and the supernatant saved. The isolation of the plasma membrane proteins was performed with the Plasma Membrane Extraction Kit (MBL International Corporation), following manufacturer instructions. The reliability of plasma membrane separation has been verified by confirming the enrichment in the plasmamembrane fraction of cadherin, a plasmamembrane marker, compared to calreticulin, an endoplasmic reticulum marker (see Text S1 and Figure S2). Protein concentration in the samples was quantified by the Bradford assay (BioRad). All protein extracts were heated at 37°C for 20 minutes in SDS-PAGE solubilising buffer (57.85 mmol/l Tris HCl, 10% Glycerol, 2% SDS, 0.004% Bromophenol blue, pH 6.8) containing 7.5% Dithiothreitol, and microfuged for 1 minute. 100 μg of total proteins or 20 μg of membrane proteins were loaded in each lane and separated by SDS-PAGE-electrophoresis on a 6.5% polyacrylamide gel at 100 V for 2 hour. Following electrophoresis, proteins were transferred overnight onto a PVDF (Polyvinylidene Fluoride) membrane. After blocking in blocking buffer 1 (PBS pH 7.4, 2% semi-skimmed milk powder, 0.05% Tween-20) for 2 hours at room temperature, the membrane was incubated with the anti-CFTR 24.1 (R&D Systems) diluted 1:1000 in the blocking buffer at 4°C overnight, followed, after several washing steps, by the secondary HRP-conjugated antibody (1:10000) at room temperature for 1 hour. Detection was performed with the Immobilon ECL system (Millipore). In all other cases, after transfer, the membrane was exposed to blocking buffer 2 (PBS pH 7.4, 5% semi-skimmed milk powder, 0.1% Tween-20) for 1 hour at room temperature. In case of reprobing of the blot, the membrane was first exposed to a stripping solution (0.05 M glycine and 1% SDS) for 40 minutes at room temperature. The membrane was then incubated with the anti-cadherin (pan Cadherin antibody, Abcam, ab6529), anti-calreticulin (Calreticulin antibody, Abcam, ab4), anti-FLAG (FLAG M2 antibody, Sigma, F3165), anti-HA (HA antibody, Covance, Princeton, NJ) or anti-CFTR (CFTR H-182 antibody, Santa Cruz, sc-10747) antibody diluted in the blocking buffer at 4°C overnight. After several washing steps, membrane was exposed to secondary HRP-conjugated antibody at room temperature for 1 hour and washed before proceeding with the ECL detection.

At the end, the PVDF membrane was always stained with the amido black staining procedure in order to assess the efficiency of protein transfer and check for equal loading.

The densitometric analyses of the bands has been performed by means of the ImageJ software (NIH, USA).
acquired between 525 and 600 nm, with a 63× (1.4 NA) oil immersion objective.

YFP-CFTR photobleaching and fluorescence recovery were analyzed in three different membrane ROIs. Fluorescence (F) recovery was followed for 150 sec.

At each time point the mean fluorescence in the ROI (FROI(t)) was corrected for the background fluorescence (Fbg(t)) and normalized for the mean fluorescence of a ROI that was not subjected to photobleaching (FnoPB(t)), subtracted of Fbg, to correct for photobleaching of YFP due to the imaging procedure:

\[
F(t) = \frac{FROI(t) - Fbg(t)}{FnoPB(t) - Fbg(t)}
\]

Finally, background and photobleaching-corrected F values were normalized for the F value measured just before photobleaching (FprePB), according to the equation:

\[
F_{\text{norm}}(t) = \frac{F(t)}{F_{\text{prePB}}}
\]

To calculate the mobile fraction (Fmob%) and the half-time constant (t1/2), each ROI fluorescence (expressed as Fnorm) recovery was individually fitted with an exponential equation as follows:

\[
F_{\text{norm}}(t) = A \times (1 - e^{-B \cdot t})
\]

with A = Fnorm_MAX represents the F value obtained by extrapolation at infinite time after recovery; B = 1/τ (1/s). τ is the first order rate constant for recovery and t1/2 (s) was calculated as τ ln 2; the mobile fraction (Fmob%) was calculated according to the following equation:

\[
F_{\text{mob}}\% = 100 \times \frac{F_{\text{norm}}\text{MAX} - F_{\text{norm}}\text{MIN}}{1 - F_{\text{norm}}\text{MIN}}
\]

where Fnorm_MIN is the first F value after photobleaching (expressed as Fnorm).

For each experimental condition, all ROIs, t1/2 and Fmob% values were averaged and the different populations were compared using Student’s t-test. All data derived from three different independent experiments.

**Photoactivation Experiments**

HEK cells were transiently transfected (PEI method) with PAGFP-CFTR and CFP-adducin WT or CFP-adducin G460W. Cells were incubated in complete medium +5 μM Ikarugamycin (Ika cells) or complete medium +0.05% DMSO (the solvent of Ika, control cells) for 2 hours before the experiments. All the experiments were performed 48 h after-transfection at 37°C, maintaining the cells in the incubation medium +HEPES 10 mM during the confocal observation. For the imaging CFP and PAGFP where excited with the 458 nm and the 488 nm laser lines, respectively, and acquired in two different PMTs with the sequential scan mode. CFP emission bandwidth: 465–490 nm, PAGFP emission bandwidth: 500–550 nm. Pixel size: 80.2 nm, scan speed: 1400 Hz, 8 bit intensity resolution. Photoactivation was performed by exciting the PAGFP for a frame with the 405 nm laser line AOTF set to 50%, scan speed: 1400 Hz. The fluorescence decay in the photoactivation region (ROI) was followed for 150 s with a frame rate of 2 fr/s. Samples expressing CFP only were used to check for possible cross-excitation of CFP during the photostimulated PAGFP imaging with the 488 nm laser line: no cross-excitation were measured with the acquisition setting used. To check for possible photobleaching during the post photostimulation time-lapse, some cells where entirely photoactivated and the fluorescence were monitored for 150 s. No photobleaching was observed during the acquisition time. The images were analyzed with ImageJ and the obtained data with the Excel software (Microsoft). Briefly, after the photoactivation, the total fluorescence in the ROI (FROI(t)) was corrected for the background (Fbg(t)) and for the fluorescence before the photoactivation (FROI(pre)−Fbg(pre)). These corrected fluorescence values were normalized (Fnorm), for each time point, by the ROI total fluorescence (background- and pre-photoactivation-corrected of the first frame after the photoactivation (FROI(0)), according to the formula:

\[
F_{\text{norm}} = \frac{(FROI(t) - Fbg(t)) - (FROI(pre) - Fbg(pre))}{(FROI(0) - Fbg(0)) - (FROI(pre) - Fbg(pre))}
\]

The data were then fitted (GraphPad Prism5 software) with a single exponential decay curve:

\[
F_{\text{norm}}(t) = F_{\text{norm}(\text{IF})} - \text{Plateau} \times e^{-K \times t} + \text{Plateau}
\]

where Plateau is the Fnorm value at infinite times and K is the rate constant (1/s). The time constant τ, expressed in [s], is the reciprocal of K. The half-life (t1/2) is ln(2)/K. For each experimental condition (normal medium, medium+DMSO or medium+Ika), the half-lives of each PAGFP-CFTR+adducin WT or PAGFP-CFTR+adducin G460W expressing cell were averaged and the different populations were compared using Student’s t-test. All data derived from three different independent experiments.

**Biotinylation Experiments**

Forty-eight hours after the transient transfection of CFTR in the HU33 and NU12 cell lines, cells were biotinylated with 1 mg/ml EZ-Link sulfo-NHS-LC-biotin (Pierce). After blocking the biotinylation reaction in PBS/100 mM glycine buffer, cells were washed in PBS and lysed in Triton buffer (25 mM Tris-HCl, 150 mM NaCl pH 7.5, Triton 1%, BSA 0.2%). The biotinylated surface proteins were allowed to bind to streptavidin beads (Ultra link immobilized streptavidine, Pierce) for 24 hours at 4°C. After three washes in lysis buffer the proteins were released from the beads by incubation with 2× SDS loading buffer, separated by 6.5% SDS-PAGE and transferred onto PVDF membrane. The blots were probed for the expression of CFTR using the primary antibody anti-CFTR 24.1 (R&D Systems), and visualized by ECL.

**cAMP Assay**

cAMP levels were determined using a cAMP-GLO assay kit (Promega) according to the manufacturers’ direction. Briefly, cells, seeded 5x10^5/well in a 96 multiwell plate 24 hours before the assay, were washed with PBS and incubated in 20 μl of induction buffer containing 10 μM forskolin or DMSO (forskolin solvent, controls). Cells were then lysed in 20 μl of cAMP-GLO lysis buffer. Lysed cell and cAMP standards were transferred to a 96-well white wall plate, and, after a 20 min incubation in 40 μl of cAMP detection solution, 80 μl of Kinase GLO reagent were...
added. Luminescence was measured with a Tecan F200 Pro luminometer. cAMP concentration was calculated using the difference between Relative Luminescence Units (RLU) values of unstimulated and stimulated cells and the equation generated from a cAMP standard curve, following manufacturers’ instructions. The assays were performed on 4 independent series of samples, and for each series every tested condition was assayed on three distinct wells and luminescence data were normalized for protein concentration.

Statistical Analysis

All the data are presented as mean ± SEM. Statistical analyses were performed using an unpaired Student’s t test or one-way or two way ANOVA (to analyse multiple data). Statistical assessments were done using the statistical package of Prism version 4 (GraphPad, San Diego, Calif.). The criterion for statistical significance was a P-value <0.05.

Results

Adducin Effects on CFTR Function: Patch-clamp Analysis in HEK Cells

To study whether the expression of adducin has functional consequences on CFTR activity, we performed whole-cell patch-clamp experiments (Figure 1) on NU12 (HEK cells stably transfected with the human wild-type adducin) and HU33 cells (expressing the G460W mutation), transiently transfected with a human CFTR expressing vector (pIREs2-EGFP-hCFTR) or with the control pIREs2-EGFP vector (data not shown). In the presence of symmetrical chloride solutions ([Cl\textsuperscript{−}] = 153 mM/L) in the pipette and bath solution, current density (i/pF, i.e. the activity expressed as overall potential differences, determined by the membrane cell potential) was not statistically different between the two cell types (−31.4±8.1 mV (n = 6) and −31.0±5.2 mV (n = 5)) in HU33 and NU12 cells respectively and was compatible with that expected for a chloride permeable channel (Figure 2B–C). The channel I/V relationship showed a pronounced rectification, differently from what observed in whole-cell experiments, and this is presumably due to the asymmetrical chloride concentration in cell-attached condition ([Cl\textsuperscript{−}] out = 151 mM/L). Channel density (number of active channels per patch, 2.8±0.5 channels/patch, n = 6 and 1.0±0.4 channels/patch, n = 5) in HU33 and NU12 cells respectively) and activity were significantly higher in HU33 than NU12 cells (Figure 2D–E). Accordingly, during voltage-ramp protocols, in which the voltage of the patch was linearly changed from −135 mV to +65 mV and allowed to directly generate current-voltage relations, the mean current (I<sub>ramp</sub>) recorded from patches containing one or more active channels was significantly lower (P<0.05) in NU12 than HU33 cells (Figure 2F). After 140 s of 10 μmol/L forskolin exposure, the I<sub>ramp</sub> increased in both NU12 and HU33 cells but it was still significantly higher (P<0.05) in HU33 than NU12 cells (Figure 2G).

Since it has been reported that actin binding protein can directly or indirectly modulate adenylate cyclase activity [37], cAMP levels were assayed using a cAMP-GLO assay kit (Promega) in HU33 and NU12 cells both before and after the addition of forskolin 10 μM to the cell culture media. cAMP levels were not significantly higher in HU33 compared to NU12 both in the presence (217451.5±77983.31 RLU (n = 4) and 113667±25298.86 RLU (n = 4) in NU12 and HU33 cells respectively, P>0.05) or in the absence (370905.9±68154.9 RLU (n = 4) and 205104.7±25875.07 RLU (n = 4) in NU12 and HU33 cells respectively, P>0.05) of forskolin. Also cAMP concentration measured as difference between unstimulated and stimulated cells was not significantly different between the two cell types (0.024026±0.011712 nM (n = 4) and 0.014316±0.002341 nM (n = 4) in NU12 and HU33 cells respectively, P>0.05).

CFTR Expression and Activity in MNS and MHS Cells

The data obtained with the transfected HEK cell line indicate that the G460W mutation of adducin induces an upregulation of CFTR activity, that is likely to be the consequence of an increased number of active channels. To verify whether this effect was detectable also in kidney cells isolated from an animal model, we performed patch-clamp experiments on distal convoluted tubule (DCT) primary cells derived from Milan hypertensive rats (MHS), bearing a F316Y hypertensive mutation, and from control normotensive rats (MNS) [38].

Cell-attached patch-clamp experiments were performed on cultured MHS and MNS primary DCT cells (Figure 3). In both cell types we observed a Cl\textsuperscript{−} channel (Figure 3B–C) characterized by a conductance of 7.45±0.41 pS (n = 3) in MNS and 8.2±0.6 pS (n = 8) in MHS cells. The current reversal potential (E<sub>rev</sub>) was −54.0±3.7 mV in MNS (n = 3) and −42.4±4.0 mV (n = 8) in MHS and the channel open probability (Po) was voltage-independent.

Further experiments were conducted to characterize this channel (Figure 3D–E). After exposure to 2 μmol/L thiazolidinone CFTR-(inh)-172 (Figure 3E) the Po was significantly reduced...
Figure 1. G460W adducin affects CFTR whole-cell current. Chloride currents in NU12 and HU33 cells overexpressing the CFTR channel (patch-clamp, whole-cell configuration). A) Representative traces of the currents recorded in NU12 (NU) and HU33 (HU) cells in the presence of symmetrical solutions (control), after the exposure to 10 μmol/L forskolin, and to 2 μmol/L CFTR-(inh)-172+10 μmol/L forskolin. B) Current-density (pA/pF) to voltage (Id-V) relation recorded in NU12 cells (NU) transfected with the pIRES2-EGFP-CFTR vector. Whole-cell currents were recorded in the presence of symmetrical chloride solutions (n = 12), 140 s after forskolin exposure (n = 12), and after CFTR-(inh)-172 inhibition (n = 12). C) Id-V relation recorded in HU33 cells (HU) transfected with the pIRES2-EGFP-CFTR vector (n = 14). The current density was significantly higher after forskolin exposure in HU.
Adducin Modulation of CFTR Activity

Adducin Effects on CFTR Surface Expression

In both models of kidney cells we found that the expression of mutated adducin results in an upregulation of CFTR activity. To assess adducin effect on CFTR expression we performed immunocytochemical experiments (Figure 3G). This pharmacological profile, along with the channel biophysical properties, matched those of CFTR, whose expression was confirmed in the MNS and MHS DCT cells by immunocytochemical experiments (Figure 3G).

Similarly to what we found in HU33 and NU12 cells, even if single channel conductance, \( E_{m} \) and \( P_{o} \) did not change significantly between MHS and MNS cells, the channel density (Figure 4A) and activity (calculated as \( N_{Po} \), Figure 4B) were significantly (\( P<0.05 \)) increased in MHS rats.

Adducin Influence on CFTR Trafficking

CFTR function is correlated to its trafficking regulation. To investigate a possible interference of mutated adducin on CFTR trafficking and diffusional mobility in the plasma membrane, we performed FRAP experiments. H9K293 T cells were transiently transfected with YFP-CFTR and CFP-adducin (Figure 7) and YFP fluorescence recovery, after YFP-CFTR photobleaching, was followed in selected regions of interest (ROIs) comprising membrane regions (Figure 7A). Quantitative image analysis was used to determine the kinetics of fluorescence recovery after photobleaching (Figure 7A-B). The percentage fluorescence recovery, generally interpreted as the fraction of mobile GFP-labeled molecules (\( F_{mob} \)), was 67.20±4.84 (\( n=38 \) experiments on cells from 3 transfection batches) for YFP-CFTR in the presence of WT adducin, a value comparable to those already reported for overexpressed-CFTR [41]. The mobility is likely to reflect both CFTR recycling and membrane internal movements, since the recovery in the lateral portion of the selected ROIs was faster than that in the central part of the ROI (central \( t_{1/2} \) 28.88±3.28 s; lateral \( t_{1/2} \) 18.41±1.55 s, \( n=26 \) experiments on cells from 3 transfection batches, \( P<0.01 \)). The co-expression with YFP-CFTR of the G460W variant significantly reduced the \( F_{mob} \) (53.18±3.88, \( n=42 \) experiments on cells from 3 transfection batches, \( P<0.05 \)). The average values half-time constant \( t_{1/2} \) for WT and G460W adducin were not significantly different (WT 28.17±2.11 s, \( n=38 \) experiments on cells from 3 transfection batches; G460W 23.63±1.47 s, \( n=42 \) experiments on cells from 3 transfection batches).

To further investigate CFTR mobility and especially the influence of adducin on its trafficking we also performed photoactivation experiments, by transiently co-expressing PAGFP-CFTR (CFTR fused to a N-t photoactivable EGFP protein) and CFP-adducin (WT or G460W) in HEK cells. Also in this case we focused on the plasma membrane region, by
Figure 2. G460W adducin affects CFTR single channel activity. Chloride currents in NU12 and HU33 cells overexpressing the CFTR channel (patch-clamp, cell-attached configuration). A) Representative single-channel traces at positive or negative potentials as indicated, recorded in NU12 (NU, left panel) or HU33 cells (HU, right panel). The dotted line corresponds to the closed level. B) Single channel current-voltage (I–V) relation for CFTR in NU12 and HU33 cells (n = 5 and 6). C) Open probability (Po) versus potential plots for CFTR channels recorded in NU12 (n = 5) and HU33 cells (n = 6). D) Channel density in NU12 (n = 5) and HU33 (n = 6) cells (N = channel density, n = total number of seals). P<0.05. E) Channel activity, measured as N multiplied by channel open probability (Po) versus membrane potential for NU12 (n = 5) and HU33 (n = 6) cells. P<0.05. F) Mean current recorded during voltage protocol consisting of ramps from −135 mV to +65 mV, applied to cell-attached patches at a rate of 0.5 mV/ms. The I/V represents the mean current of 10 ramp protocols from 5 and 6 patch of NU12 and HU33 cells respectively. In the box representative single ramp records are reported for NU12 (upper ramp) and HU33 (lower ramp). G) Mean current recorded in the same condition as in F, after 3 minutes exposure to 10 μmol/L forskolin.
doi:10.1371/journal.pone.0052014.g002
photoactivating PAGFP-CFTR in ROIs comprising membrane portions and monitoring the decrease in time of the fluorescence (Figure 8A). The half time constant (t1/2), calculated by fitting the resulting curves with an exponential decay function, was 21.13 ± 1.80 s (n = 30 experiments on cells from 3 transfection batches) in the presence of WT-adducin and was significantly (P < 0.05) increased when G460W adducin was expressed (t1/2 = 28.35 ± 3.12, n = 29 experiments on cells from 3 transfection batches, Figure 8C), thus confirming that the mutation of adducin causes a reduced CFTR mobility in the membrane region. The effect of G460W adducin on PA-CFTR mobility was similar, even if less intense, to that obtained by treating WT adducin transfected cells with ikarugamycin (Figure 8B, t1/2 = 22.07 ± 1.40, n = 20 experiments on cells from 3 transfection batches for control; t1/2 = 54.04 ± 8.57, n = 19 experiments on cells from 3 transfection batches for IKA; P < 0.05), that acts as a general inhibitor of clathrin-coated pit-mediated endocytosis and has been used in endocytosis study [42,43].

Discussion

Several studies proved that CFTR activity is influenced by actin cytoskeleton and its polymerization state [26]. In this study we demonstrate that in G460W α-adducin expressing cells and in isolated DCT cells of MHS rats the activity of the CFTR channel increases as well. The expression of the hypertensive mutation of adducin leads to a functional modification of CFTR activity, as observed in the...
patch-clamp experiments performed on HU33/NU12 stably transfected HEK cells. The forskolin activated whole-cell CFTR current recorded at maximal activation was significantly (P, 0.05) higher in HU33 cells, expressing the hypertensive variant of adducin, than in NU12 cells, expressing the WT variant. The increase in current density at maximal activation, along with the observation that the slope of the activation, but not the t50, significantly increased, suggests a higher CFTR density in the plasmamembrane of G460W adducin expressing cells. The single channel experiments evidenced that the mutation of adducin associates with an increased channel activity both before and after forskolin exposure and CFTR activation. Measurements of intracellular cAMP level indicate that this is not due to an upregulation of the cAMP pathway in HU33 cells. Consistently with this hypothesis, the experiments performed on MNS/MHS rats indicate that this effect is reproducible also in cultured primary DCT cells, isolated from the animal hypertensive models. DCT is involved in hypertension maintenance in the MHS rats, in which the expression and activity of both Na⁺-Cl⁻ cotransporter and ClC-K increase [11], and the Na⁺/K⁺ pump is upregulated [12]. The experiments evidenced that the mutation of adducin in MHS rat DCT cells correlates with an increased CFTR channel density and activity, suggesting that CFTR could be directly or indirectly involved in the general alteration of renal ion transport in essential hypertension. Nowadays, despite the relatively high expression of CFTR in the kidney, its role in this organ is still elusive [19] and it has been hypothesized that CFTR could not only secrete but also absorb Cl⁻ across the apical membrane of distal tubules, at least when Na⁺ absorption is stimulated and the apical membrane potential depolarized [22], therefore contributing to the increased transcellular NaCl reabsorption observed in hypertension. It is possible that in the kidney its regulatory role might be more relevant than its activity as a chloride channel. It has recently been proposed that its membrane localization could influence both cytoskeletal organization and compartmentalization of signaling molecules such as cAMP and PKA in the subcortical compartment [44]. Moreover, CFTR is also known as a modulator of the activity of others transport systems, such as the ROMK K⁺ channel and the ENaC Na⁺ channel [19,45]. Several studies have demonstrated in vivo an inverse relation between the putative CFTR levels and the expression of ENaC [46]. At a first glance, these observations are difficult to reconcile with the hypothesis that an increase of CFTR in the membrane would result in an increase of the NaCl intake, but could rather suggest that the increased surface expression of CFTR could help in counteracting the pathologically increment of salt uptake in the hypertensive subjects. Yet, the interaction between CFTR and ENaC seems to be more complex and dependent on the cell type: the activation of CFTR inhibits ENaC in airways cells [46,47] and colonic cells [48], whereas it is accompanied by the concomitant activation of ENaC in absorptive sweat gland cells [49], in CCD kidney cells.

Figure 4. CFTR density and activity. A) Channel density in MNS (n = 35) and MHS (n = 22) DCT cells (N = channel density, n = total number of seals). *P < 0.05. B) Channel activity (NxPo, measured as N multiplied by channel Po) versus membrane potential (V) for MNS (n = 35) and MNS (n = 22) channels. *P < 0.02 when comparing the two data sets.

doi:10.1371/journal.pone.0052014.g004

Figure 5. Expression of total CFTR protein (fully and core glycosylated) in NU12 and HU33 cells. A) Western blot analysis of CFTR expression in NU12 and HU33 cells transiently transfected with the pcDNA3-CFTR vector; arrows indicate the core-glycosylated (band B) and fully glycosylated (band C) forms of CFTR. The blot was probed with anti-CFTR antibody (top panel) and anti-cadherin antibody (lower panel). B) Densitometric analysis of the ratio of total CFTR (band C/band B)/cadherin band intensities (OD CFTR/OD Cad: n = 7 for NU12, n = 6 for HU33); ns = non significative. Only samples showing both CFTR and cadherin clear signals were considered for the quantitative analysis.

doi:10.1371/journal.pone.0052014.g005
Therefore, in epithelial cells, that are actively involved in Cl− secretion, the effect of activating CFTR (e.g., by cAMP, forskolin, or cholera toxin) would result in a fall in intracellular Cl− concentration, and therefore in ENaC-mediated Na+ absorption [52].

The inhibitory effect of CFTR in some preparations may be due to the rise it produces in intracellular Cl− concentration rather than to a direct molecular interaction of CFTR with ENaC. Therefore, in epithelial cells, that are actively involved in Cl− secretion and absorption, and where chloride is maintained above its electrochemical equilibrium value, the effect of activating CFTR (e.g., by cAMP, forskolin, or cholera toxin) would result in a fall in intracellular Cl− concentration, and therefore in ENaC-mediated Na+ absorption [52]. In agreement with this observation, Xie and Shafer [51] demonstrated that the treatment with cAMP stimulates Cl− secretion via cystic fibrosis transmembrane conductance regulator as well as ENaC-mediated Na+ absorption in MDCK cells. This could be in agreement with a lack of a kidney phenotype in cystic fibrosis patients [33,34], in which CFTR activity is compromised, but chloride intracellular concentration could be modulated by the plethora of chloride channels [53] and transporters [56] that are active in kidney cells.

An involvement of CFTR in the renal regulation of extracellular fluid volume (ECFV) and, hence, in trans epithelial transport, is additionally suggested by the observation that ECFV regulatory hormones, such as vasopressin or thyroid hormone, increase CFTR expression in the kidney [57,58]. Actually it has already been proposed that an enhancement of CFTR activity could be involved in the pathogenesis of cystic fibrosis patients [33,34], in which CFTR activity is compromised, but chloride intracellular concentration could be modulated by the plethora of chloride channels [53] and transporters [56] that are active in kidney cells.

An involvement of CFTR in the renal regulation of extracellular fluid volume (ECFV) and, hence, in trans epithelial transport, is additionally suggested by the observation that ECFV regulatory hormones, such as vasopressin or thyroid hormone, increase CFTR expression in the kidney [57,58]. Actually it has already been proposed that an enhancement of CFTR activity could be involved in the pathogenesis of cystic fibrosis patients [33,34], in which CFTR activity is compromised, but chloride intracellular concentration could be modulated by the plethora of chloride channels [53] and transporters [56] that are active in kidney cells.

An involvement of CFTR in the renal regulation of extracellular fluid volume (ECFV) and, hence, in trans epithelial transport, is additionally suggested by the observation that ECFV regulatory hormones, such as vasopressin or thyroid hormone, increase CFTR expression in the kidney [57,58]. Actually it has already been proposed that an enhancement of CFTR activity could be involved in the pathogenesis of cystic fibrosis patients [33,34], in which CFTR activity is compromised, but chloride intracellular concentration could be modulated by the plethora of chloride channels [53] and transporters [56] that are active in kidney cells.

An involvement of CFTR in the renal regulation of extracellular fluid volume (ECFV) and, hence, in trans epithelial transport, is additionally suggested by the observation that ECFV regulatory hormones, such as vasopressin or thyroid hormone, increase CFTR expression in the kidney [57,58]. Actually it has already been proposed that an enhancement of CFTR activity could be involved in the pathogenesis of cystic fibrosis patients [33,34], in which CFTR activity is compromised, but chloride intracellular concentration could be modulated by the plethora of chloride channels [53] and transporters [56] that are active in kidney cells.

As a whole, additional studies are needed to better clarify the link between CFTR and kidney pathophysiology.

In this work we tried to further investigate the molecular mechanisms by which adducin could regulate CFTR activity.

In HEK cells overexpressing adducin, the measured increased activity of CFTR is paralleled by an altered processing efficiency of CFTR in the G460W adducin expressing cells: Western blot experiments revealed an increase of the ratio between the fully glycosylated band C and the core-glycosylated band B expression in HU33 compared with NU12 cells. The fully glycosylated band C of CFTR represents its mature form, predominantly located in the plasmamembrane and in the recycling submembrane vesicles, while band B represents the immature form of CFTR typical of the endoplasmic reticulum [39,61]. The increase in the amount of plasmamembrane band C does not seem to be a consequence of a change in the total amount of CFTR (band B+C, Figure 5) and could be either due to an increase in the glycosylation efficiency or to a reduction of endocytosis, leading to a reduced turnover and to a longer retention of mature CFTR into the membrane. Channel glycosylation influences CFTR turnover in the post-endoplasmic reticulum compartments, with the fully glycosylated channel being more stable [62,63], whereas it does not influence channel activity [62]. Therefore the enhancement of channel glycosylation observed in HU33 cells could lead to the observed increase of channel surface expression, revealed both by the Western blot experiments performed on the plasma membrane protein fraction and by biotinylation experiments (Figure 6), resulting in an increased number of active channels. Anyway, while no reports link adducin to glycosylation pathways, it has already been demonstrated that the expression of the mutated adducin reduces the endocytosis of Na+/K+-ATPase [8,14] and of AQP4 water channel [64], suggesting that a similar mechanism is more likely to be directly involved also in the observed enhancement of CFTR surface expression and channel density.

To further investigate this point, we focused on CFTR-adducin interaction and CFTR trafficking.

FRET experiments demonstrated a faint but significative FRETeff that might imply a close vicinity (in the nm range) between CFTR and adducin. The FRETeff was not significantly changed in the presence of the mutated G460W adducin variant both in the basal state or after the channel activation with forskolin. Anyway, immunoprecipitation experiments failed to

---

Figure 6. Expression of CFTR in the plasmamembrane fraction in NU12 and HU33 cells. A) Western blot analysis of CFTR expression in NU12 and HU33 cells transiently transfected with the pcDNA3-CFTR vector; only one band at a molecular weight compatible with that of band C (~160 kDa) is visible in the plasmamembrane fraction. The blot was probed with anti-CFTR antibody (top panel) and anti-cadherin antibody (lower panel). B) Densitometric analysis of the ratio of plasmamembrane CFTR/cadherin band intensities (OD CFTR/OD Cad, n = 6). *P<0.05. C) Western blot analysis of biotinylated CFTR in NU12 and HU33 cells transiently transfected with the pcDNA3-CFTR vector. CFTR signal (anti-CFTR antibody) in cell lysates (lysates, upper panel) and in the cell surface fraction (surface, lower panel) are reported. Only one band compatible with band C is detectable in the cell surface fraction. No biotinylation condition served as control (HU12 ctrl; HU33 ctrl).

doi:10.1371/journal.pone.0052014.g006
Figure 7. G460W adducin influences CFTR trafficking: FRAP experiments. A) Cell images from a FRAP experiment: YFP-CFTR signal in a HEK293 T cell over-expressing CFP-WT adducin (Add-WT, upper panels) or CFP-G460W adducin (Add-G460W, lower panels) before YFP photobleaching (pre PB) and at different time-points after the photobleaching (post PB t = 0 s, 20 s, 50 s); on the right the corresponding CFP-adducin signal (Add) is reported for each condition. In the pre-photobleaching images three membrane ROIs are shown. Scale bar is 5 μm. The graph shows the kinetics of CFTR-YFP fluorescence recovery after photobleaching in presence of the CFP-adducin WT or G460W mutated variant. B) Mean CFTR mobile fraction percentage (F_{mob}%) and mean half-life constants (t_{1/2}) of HEK cells over-expressing YFP-CFTR and CFP-WT adducin (n = 38) or CFP-G460W adducin (n = 42). *P<0.05.

doi:10.1371/journal.pone.0052014.g007

Adducin Modulation of CFTR Activity

PLOS ONE | www.plosone.org 12 December 2012 | Volume 7 | Issue 12 | e52014
reveal a clear co-immunoprecipitation of CFTR with adducin, suggesting that, if any, the possible interaction between the two proteins is likely to be feeble and unstable as already reported for the interaction between CFTR and actin mediated by intermediate cytoplasmic proteins [41].

Direct binding is not the only way by which adducin could modulate CFTR channel activity and affect its surface expression. CFTR, as adducin, forms a submembrane complex with several proteins, comprising actin [5,35] or AP-2 [14,65]. Adducin mutations could act by altering CFTR traffic, both through the modulation of cytoskeleton dynamics [26] and/or through affecting of AP2-μ2 phosphorylation [65], as already reported for the Na+/K+ pump [8,14]. To investigate this point we performed both FRAP and photoactivation experiments. In both cases we found a rather high mobility of CFTR in the ROIs comprising plasmamembrane portions (70–52% F_{mob} for FRAP), with a comparable t_{1/2}. The values of F_{mob} are similar to those obtained in other studies [41,66] and the relatively high

Figure 8. G460W Adducin influences CFTR trafficking: photoactivation experiments. A) Cell images from a photoactivation experiment: PAGFP-CFTR signal in a HEK293 T cell over-expressing CFP-WT adducin in control conditions (contr, upper panels) or in presence of ikarugamycin (ika, lower panels), an inhibitor of endocytotic recycling. Different time-points after photoactivation are shown (t = 0 s, 20 s, 50 s), together with the bright field images and the CFP-adducin signals (Add). In the bright field images the membrane ROIs are evidenced. Scale bar is 5 μm. B) Representative traces showing the kinetics of fluorescence decay after PAGFP-CFTR photoactivation in HEK cells over-expressing CFP-WT adducin exposed to ikarugamycin (ika, n = 19) or in control conditions (contr, n = 20). Mean half-lives (t_{1/2}) are shown. *P<0.05. C) Representative traces showing the kinetics of fluorescence decay after PAGFP-CFTR photoactivation in HEK cells over-expressing CFP-adducin WT (WT, n = 30) or G460W mutated (G460W, n = 29) variant. Mean half-life constants (t_{1/2}) are shown. *P<0.05.
doi:10.1371/journal.pone.0052014.g008
mobility, especially of WT-CFTR, is likely to be a consequence of overexpression, as already proposed [66,67]. Moreover, at least part of the measured CFTR mobility is depending on lateral membrane diffusion, as proven, in the case of the FRAP experiments, by the lower $t_{1/2}$ measured for the lateral portions of the ROIs, compared to the central ones. Yet, both FRAP and photoactivation experiments indicate that CFTR is more and/or longer retained in the membrane area when mutant adducin is co-expressed, according to the hypothesis that the mutations of adducin alter CFTR membrane mobility and apparently lower its membrane turnover. The effect of G460W adducin on PA-CFTR longer retained in the membrane area when mutant adducin is co-photoactivation experiments indicate that CFTR is more and/or of the ROIs, compared to the central ones. Yet, both FRAP and mobility. Therefore, the retention of CFTR in the membrane area might be the consequence both of a reduced endocytosis and of an increased mobility of actin cytoskeletal stiffness induced by the mutated forms of adducin, that could exert an inhibitory effect on membrane protein lateral mobility [70,71] and traffic [8,72].

In conclusion, despite several hypotheses concerning CFTR involvement in hypertension, our study is, to our knowledge, the first to demonstrate a connection between CFTR and adducin, showing that channel activity is increased in isolated DCT cells of hypertensive MHS rats and in HEK cells overexpressing an hypertensive variant of adducin. In renal cell models, adducin mutations are likely to influence CFTR activity by affecting its membrane turnover, leading to a reduction of the channel in the plasmamembrane.

Since CFTR is known to modulate the activity of many others transport systems, the increased surface expression of the channel could have consequences on the whole network of transport in the kidney cells. Further studies and additional analyses, either genetic or functional, on hypertensive patients as well, will help to fully understand the importance of CFTR in the modification of renal NaCl absorption in vivo.

Supporting Information

**Figure S1** Adducin expression in NU12 and HU33 cells.
A) Western blot analysis of HA-adducin expression in NU12 ($\mathcal{N}_{u1}$, $\mathcal{N}_{u2}$) and HU33 ($\mathcal{H}_{u1}$, $\mathcal{H}_{u2}$) cells, compared with non transfected HEK cells ($\mathcal{N}_{T}$, $\mathcal{N}_{T'}$). Two independent preparations are shown for each condition. The blot was probed with anti-HA antibody.
B) Confocal images showing HA-adducin expression in NU12 ($\mathcal{N}$) and HU33 ($\mathcal{H}$) cells, together with bright field images. Primary antibody anti-HA, secondary antibody Alexa 488 anti-mouse; in the control condition (contra) the primary antibody was omitted. Scale bar is 10 μm.

**Figure S2** Assessment of HU33/NU12 transfection efficiency and plasma membrane protein enrichment. A) Confluent images showing CFTR expression in HU33 (upper panels) and NU12 (lower panels) cells, transfected with pcDNA3-CFTR plasmid (HU CFTR, NU CFTR, left), non transfected NU and HU cells (HU NT, NU NT, right) served as control. Primary antibody: anti-CFTR, secondary antibody: Alexa 568 anti-mouse; nuclei are stained in blue (DAPI). Scale bar is 10 μm. Histograms illustrate the percentage of transfected NU12 ($\mathcal{N}$) and HU33 ($\mathcal{H}$) cells, showing no significant differences in transfection efficiency ($n = 11$). B) Transfection efficiency was also assessed with the Renilla luciferase reporter assay, NU12 and HU33 cells were cotransfected with pcDNA3-CFTR and pRL-TK (renilla luciferase reporter gene under the control of thymidine kinase promoter) plasmids, thus allowing the evaluation of cells transfection efficiency. The two histograms show luciferase activity normalized for the number of cells (AU lumino/m/NT) the total protein amount (AU lumino/m/ct). (TIF)

**Figure S3** Interaction between adducin and CFTR: FRET experiments. The acceptor photobleaching method was used to obtain the FRET efficiency. A) Cell images of the CFP (CFP, upper panel) and YFP (YFP-CFTR, lower panel) channel before (pre-bleach) and after (post-bleach) the YFP photobleaching and FRET efficiency images (FRET) for HEK cells overexpressing CFP and YFP-CFTR (control). Scale bar is 10 μm. B) Cell images of the CFP (Add-CFP, upper panel) and YFP (YFP-CFTR, lower panel) channel before and after the YFP photobleaching and FRET efficiency images (FRET) for HEK cells overexpressing CFP-adducin WT and YFP-CFTR. Scale bar is 10 μm. C) FRET efficiency (FRETeff %) measured in control cells (CFP+Y-CFTR, n = 27) and in cells overexpressing YFP-CFTR and the CFP-adducin WT (Y-CFTR+C-Add WT, n = 40) or the G460W mutated variant (Y-CFTR+C-AddG460W, n = 35). **P < 0.01. D) FRET efficiency (FRETeff %) measured after 10 μmol/L forskolin exposure in control cells (CFP+Y-CFTR, n = 4) and in cells overexpressing YFP-CFTR and the GFP-adducin, WT (Y-CFTR+C-Add WT, n = 11) or G460W mutated variant (Y-CFTR+C-AddG460W, n = 9). **P < 0.05. (TIF)

**Figure S4** Interaction between adducin and CFTR: immunoprecipitation experiments. A) Immunoprecipitation experiment on HEK cells cotransfected with pcDNA3-CFTR and pcDNA3.1-WT adducin-FLAG (C-terminal FLAG tag, Add-
FLAG; pcDNA3-CFTR and pFLAG-CMV4-BAP (bovine alkaline phosphatase, FLAG-BAP) cotransfection served as control. CFTR signal (upper panel; anti-CFTR antibody) and FLAG signal (lower panel; anti-FLAG antibody) in cell lysates (Lys), flow through (FT) and fixed sequential 40 μl eluates (E1–E5) are shown. B. Immunoprecipitation experiments on HEK cells cotransfected with pcDNA3-CFTR and pcDNA3.1-HA-WT adducin (N-terminal HA-tag, HA-add), pcDNA3-CFTR and empty pFLAG-CMV4 plasmid cotransfection served as control (ctrl), CFTR signal (upper panel; anti-CFTR antibody) and HA signal (lower panel; anti-HA antibody) in cell lysates (Lys) and eluates (E) from 2 and 24 hours incubation with anti-HA agarose affinity gel are shown. Subscripts A and B refer to two independent preparations. (TIF)

Figure S5 Actin and adducin staining in NU12 and HU33 cells. Confocal images showing actin (Act, left) and adducin (Add, right) in NU12 (HU, upper panels) and NU12 (HU, lower panels) cells. Primary antibody: anti-HA; secondary antibody: Alexa 488 anti-mouse. Actin fibers were stained with Alexa 568 Phalloidin. Scale bar is 10 μm.

References
1. Kuhlman PA, Hughes CA, Bennett V, Fowler VM (1996) A new function for adducin. Calcium/calmodulin-regulated capping of the barbed ends of actin filaments. J BioChem 271: 7986–7991.

2. Mische SM, Mosser MS, Morcos JS (1998) Erythrocyte adducin: a calmodulin-regulated actin-binding protein that stimulates actin-actin binding. J Cell Biol 105: 2817–2845.

3. Gardner K, Bennett V (1998) Modulation of specrin-actin assembly by erythrocyte adducin. Nature 329: 359–362.

4. Li X, Matsuoka Y, Bennett V (1998) Adducin preferentially recruits spectrin to the fast growing ends of actin filaments in a complex requiring the MARKS-related domain and a newly defined oligomerization domain. J BioChem 235: 19329–19335.

5. Bennett V, Baines AJ (2001) Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. Physiol Rev 81: 1333–1392.

6. Naydenov NG, Ivanov AI (2010) Adducins regulate remodeling of apical junctions in human epithelial cells. Mol Biol Cell 21: 3506–3517.

7. Kaiser HW, O’Keefe E, Bennett V (1989) Adducin. Ca++-dependent association with sites of cell-cell contact. J Cell Biol 109: 557–569.

8. Torielli L, Tisodor S, Montella RC, Iacone R, Padoani G, et al. (2008) Alpha-Adducin mutations increase Na+/K-pump activity in renal cells by affecting constitutive endocytosis: implications for tubular Na reabsorption. Am J Physiol Renal Physiol 295: F478–F487.

9. Tripodi G, Valtorta F, Torielli L, Chieregatti E, Salardi S, et al. (1996) Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. J Clin Invest 97: 2013–2022.

10. Bianchi G, Baer PG, Fox U, Duzzi L, Pagetti D, et al. (1975) Changes in renin, aldosterone and uric acid in genetic hypertension. Hypertension 36: 153–161.

11. Capasso G, Rizzo M, Garavaglia ML, Trepiccione F, Zacchia M, et al. (2008) Evidence for a genetic component in the renal sodium-potassium pump activity of rats of different strains. J Physiol 592: 661–674.

12. Ferrandi M, Molinari I, Torielli L, Padoani G, Salardi S, et al. (2010) Adducin and five sequential 40 μl eluates (E1–E5) are shown. B. Immunoprecipitation experiments on HEK cells cotransfected with pcDNA3-CFTR and pcDNA3.1-HA-WT adducin (N-terminal HA-tag, HA-add), pcDNA3-CFTR and empty pFLAG-CMV4 plasmid cotransfection served as control (ctrl), CFTR signal (upper panel; anti-CFTR antibody) and HA signal (lower panel; anti-HA antibody) in cell lysates (Lys) and eluates (E) from 2 and 24 hours incubation with anti-HA agarose affinity gel are shown. Subscripts A and B refer to two independent preparations. (TIF)

Figure S5 Actin and adducin staining in NU12 and HU33 cells. Confocal images showing actin (Act, left) and adducin (Add, right) in NU12 (HU, upper panels) and NU12 (HU, lower panels) cells. Primary antibody: anti-HA; secondary antibody: Alexa 488 anti-mouse. Actin fibers were stained with Alexa 568 Phalloidin. Scale bar is 10 μm.

References
1. Kuhlman PA, Hughes CA, Bennett V, Fowler VM (1996) A new function for adducin. Calcium/calmodulin-regulated capping of the barbed ends of actin filaments. J BioChem 271: 7986–7991.

2. Mische SM, Mosser MS, Morcos JS (1998) Erythrocyte adducin: a calmodulin-regulated actin-binding protein that stimulates actin-actin binding. J Cell Biol 105: 2817–2845.

3. Gardner K, Bennett V (1998) Modulation of specrin-actin assembly by erythrocyte adducin. Nature 329: 359–362.

4. Li X, Matsuoka Y, Bennett V (1998) Adducin preferentially recruits spectrin to the fast growing ends of actin filaments in a complex requiring the MARKS-related domain and a newly defined oligomerization domain. J BioChem 235: 19329–19335.

5. Bennett V, Baines AJ (2001) Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. Physiol Rev 81: 1333–1392.

6. Naydenov NG, Ivanov AI (2010) Adducins regulate remodeling of apical junctions in human epithelial cells. Mol Biol Cell 21: 3506–3517.

7. Kaiser HW, O’Keefe E, Bennett V (1989) Adducin. Ca++-dependent association with sites of cell-cell contact. J Cell Biol 109: 557–569.

8. Torielli L, Tisodor S, Montella RC, Iacone R, Padoani G, et al. (2008) Alpha-Adducin mutations increase Na+/K-pump activity in renal cells by affecting constitutive endocytosis: implications for tubular Na reabsorption. Am J Physiol Renal Physiol 295: F478–F487.

9. Tripodi G, Valtorta F, Torielli L, Chieregatti E, Salardi S, et al. (1996) Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. J Clin Invest 97: 2013–2022.

10. Bianchi G (2005) Genetic variations of tubular sodium reabsorption leading to “primary” hypertension: from gene polymorphism to clinical symptoms. Am J Physiol Renal Physiol Comp Physiol 289: R1536–R1549.

11. Capasso G, Rizzo M, Garavaglia ML, Torielli L, Padoani G, et al. (2008) Uregulation of apical sodium-chloride cotransporter and basolateral chloride channels is responsible for the maintenance of salt-sensitive hypertension. Am J Physiol Renal Physiol 295: F556–F567.

12. Ferrandi M, Tripodi G, Salardi S, Filorrio M, Modica R, et al. (1996) Renal Na+,K-ATPase in genetic hypertension. Hypertension 28: 1018–1025.

13. Ferrandi M, Salardi S, Tripodi G, Barassi P, Rivera R, et al. (1999) Evidence for an interaction between adducin and Na(+)/K(+)-ATPase: relation to genetic hypertension. Am J Physiol 277: H1338–H1349.

14. Einfeldt R, Kormar RT, Ogimoto G, Zschill J, Tripodi G, et al. (2004) Hypertension-linked mutation in the adducin alpha-subunit leads to higher Ap2-mu2 phosphorylation and impaired Na(+)/K(+)-ATPase trafficking in response to GPCR signals and intracellular sodium. Circ Res 95: 1100–1108.

15. Ferrandi M, Molinari I, Torielli L, Padoani G, Salardi S, et al. (2010) Adducin and obsatin-related gene variants predict the antihypertensive activity of rostafuroxin, part 1: experimental studies. SciTransMed 2: 59ra86.

16. Bianchi G, Baer PG, Fox U, Duzzi L, Patetti D, et al. (1975) Changes in renin, aldosterone and uric acid in genetic hypertension. Hypertension 36: 153–161.

17. Carmonoso M, Rizzo F, Ferrari P, Torielli L, Ferrandi M, et al. (2011) NKKC3 is activated in Milan hypertensive rats contributing to the maintenance of salt-sensitive hypertension. PloS Arch 462: 281–291.

18. Capasso G, Rizzo M, Evangelista G, Ferrari P, Grelen G, et al. (2005) Altered expression of renal apical plasma membrane Na+ transporters in the early phase of genetic hypertension. Am J Physiol Renal Physiol 288: F1173–1162.

(TIF)

Text S1 Supplementary methods. Additional methodological information concerning the results presented in the supplementary figures, i.e. evaluation of transfection efficiency, fluorescence resonance energy transfer (FRET) experiments, immunoprecipitation, HA-adducin and actin staining of HU33/NU12 cells. (DOC)

Acknowledgments
The authors wish to thank Dr. Guido Botta and Dr. Valeria Rossetti for the useful discussion.

Author Contributions
Conceived and designed the experiments: AM MLG CB SR. Performed the experiments: AM FS MLG CB SR DAG VV. Analyzed the data: AM FS MLG CB SR GM. Contributed reagents/materials/analysis tools: PC LT GC MP SR. Wrote the paper: AM FS MLG CB GM.

Adducin Modulation of CFTR Activity
38. Bianchi G, Tripodi G, Gasari G, Salardi S, Barber BR, et al. (1994) Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci USA 91: 3999–4003.

39. O’Kordan CR, Larchapelle AL, Marshall J, Higgins EA, Cheong SH (2000) Characterization of the oligosaccharide structures associated with the cystic fibrosis transmembrane conductance regulator. Glycobiology 10: 1225–1233.

40. Ban H, Iinoue M, Griesenbach U, Munkonge F, Chan M, et al. (2007) Expression and maturation of Sendai virus vector-derived CFTR protein: functional and biochemical evidence using a GFP-CFTR fusion protein. Gene Ther 14: 1688–1694.

41. Haggie PM, Stanton BA, Verkman AS (2004) Increased diffusional mobility of CFTR at the plasma membrane after deletion of its C-terminal PDZ binding motif. J Biol Chem 279: 5494–5500.

42. Luo T, Frederiksen BL, Hassani K, Endo A, Garcia JV (2001) Human immunodeficiency virus type 1 Nef-induced CD4 surface downregulation is inhibited by interleukin 10. J Virol 75: 2480–2492.

43. Moscatelli A, Ciampolini F, Rodighiero S, Occhi E, Creati M, et al. (2007) Distinct endocytic pathways identified in tobacco pollen tubes using charged nanogold. J Cell Sci 120: 3804–3819.

44. Monteris S, Favia M, Guerra L, Cardone RA, Marzulli D, et al. (2012) CFTR regulated apical chloride channels in cortical collecting duct. Proc Natl Acad Sci U S A 109: 6082–6087.

45. Lu M, Dong K, Egan ME, Giebisch GH, Boulpaep EL, et al. (2010) Mouse cystic fibrosis transmembrane conductance regulator forms cAMP-PKA-regulated apical chloride channels in cortical collecting duct. Proc Natl Acad Sci USA 107: 6072–6077.

46. Lazrak A, Jurkenenaitė A, Chen L, Keeling KM, Collawn JF, et al. (2011) Enhancement of alveolar epithelial sodium channel activity with decreased cystic fibrosis transmembrane conductance regulator expression in mouse lung. Am J Physiol Lung Cell Mol Physiol 301: L557–567.

47. Mall M, Biech M, Greger R, Kunzelmann K (1998) The amiloride-inhibitable Na+ conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways. J Clin Invest 102: 15–21.

48. Kunzelmann K, Greger R, König J, Mall M (2002) Ion transport induced by adenosine 3′,5′-monophosphate at the plasma membrane. J Biol Chem 276: 46251–46259.

49. Reddy MM, Light MJ, Quonion PM (1999) Activation of the epithelial Na+ channel (ENaC) requires CFTR Cl− channel function. Nature 402: 301–304.

50. Chang CT, Bens M, Hummler E, Boulkroun S, Schild L, et al. (2005) Arginine vasopressin regulates CFTR and ClC-2 mRNA expression in rat kidney cortex and medulla. Pflugers Arch 452: 302–311.

51. Xie Y, Schafer JA (2004) Inhibition of ENaC by intracellular Cl− in an MDCK cell line expressing a CFTR mutant with high ENaC expression. Am J Physiol Renal Physiol 287: F722–731.

52. Kunzelmann K (2004) ENaC is inhibited by an increase in the intracellular Cl− concentration mediated through activation of Cl−/HCO3− channels. Pflugers Arch 445: 504–512.

53. Leiberman J, Rodbard S (1975) Loss of blood pressure in young adults with cystic fibrosis: an effect of chronic salt loss in sweat? Am Intern Med 82: 806–808.

54. Super M, Irtiza-Ali A, Roberts SA, Schwarz M, Young M, et al. (2004) Blood pressure and the cystic fibrosis transmembrane conductance regulator: an effect of chronic salt loss in sweat? Am Intern Med 82: 806–808.

55. Veizis IE, Cotton CU (2007) Role of kidney chloride channels in health and disease. Pediatr Nephrol 22: 770–777.

56. Bernstein PL, Ellison DH (2011) Diuretics and salt transport along the nephron. Semin Nephrol 31: 475–482.

57. de Andrade Pinto AC, Barbosa CM, Ornelas DS, Novaia HJ, de Souza-Menezes J, et al. (2007) Thyroid hormones stimulate renal expression of CFTR. Cell Physiol Biochem 20: 83–90.

58. Morales MM, Nascimento DS, Capella MA, Lopes AG, Guggino WB (2001) Arginine vasopressin regulates CFTR and Cl−/HCO3− expression in rat kidney cortex and medulla. Pflugers Arch 445: 302–311.

59. Baker EH, Portal AJ, McElvaney TA, Blackwood AM, Miller MA, et al. (1999) Epithelial sodium channel activity is not increased in hypertension in whites. Hypertension 33: 1031–1035.

60. Bates IR, Hebert B, Liao Y, Liao J, Bachir AI, et al. (2006) Membrane lateral diffusion and capture of CFTR within transient confinement zones. Biophys J 91: 1046–1058.

61. Haggie PM, Kim JK, Lukacs GL, Verkman AS (2006) Tracking of quantum dot-labeled CFTR shows near immobilization by C-terminal PDZ interactions. Mol Biol Cell 17: 4937–4945.

62. Karpushov AV, Ratovskaya DV, Pavlov TS, Nenegaeva YA, Staruschchenko A (2010) Intact cystoskeleton is required for small G protein-dependent activation of the epithelial Na+ channel. PLoS One 5: e11827.

63. Penmatsa H, Zhang W, Yarlagadda S, Li C, Conoley VG, et al. (2010) Compartmentalized cyclic adenosine 3′,5′-monophosphate at the plasma membrane clusters PDE1A and cystic fibrosis transmembrane conductance regulator into microdomains. Mol Biol Cell 21: 1097–1110.

64. Won S, Lee BC, Park CS (2011) Functional effects of cytoskeletal components on epithelial sodium channel activity. J Physiol 588: 819–830.

65. Wenzel KM, Bradbury NA (2001) Mu 2 binding directs the cystic fibrosis transmembrane conductance regulator to the clathrin-mediated endocytic pathway. J Biol Chem 276: 46521–46529.

66. Bates IR, Hébert B, Liao Y, Liao J, Bachir AI, et al. (2006) Membrane lateral diffusion and capture of CFTR within transient confinement zones. Biophys J 91: 1046–1058.

67. Haggie PM, Kim JK, Lukacs GL, Verkman AS (2006) Tracking of quantum dot-labeled CFTR shows near immobilization by C-terminal PDZ interactions. Mol Biol Cell 17: 4937–4945.

68. Karpushov AV, Ratovskaya DV, Pavlov TS, Nenegaeva YA, Staruschchenko A (2010) Intact cystoskeleton is required for small G protein-dependent activation of the epithelial Na+ channel. PLoS One 5: e11827.

69. Penmatsa H, Zhang W, Yarlagadda S, Li C, Conoley VG, et al. (2010) Compartmentalized cyclic adenosine 3′,5′-monophosphate at the plasma membrane clusters PDE1A and cystic fibrosis transmembrane conductance regulator into microdomains. Mol Biol Cell 21: 1097–1110.

70. Won S, Lee BC, Park CS (2011) Functional effects of cytoskeletal components on the lateral movement of individual BKCa channels expressed in live COS-7 cell membrane. FEBS Lett 585: 2323–2330.

71. Jin S, Haggie PM, Verkman AS (2007) Single-particle tracking of membrane protein diffusion in a potential: simulation, detection, and application to confined diffusion of CFTR Cl− channels. Biophys J 93: 1079–1088.

72. Qualman B, Kessels MM (2002) Endocytosis and the cytoskeleton. Int Rev Cytol 220: 93–144.